The COVID-19 pandemic has lasted more than one year, and vaccines are the primary expectation of ending it. The vaccine development successfully accelerated from 10-15 years to only about 12-16 months through several adjustments. In a health crisis, the vaccine can be accepted through Emergency Use Authorization (EUA) by a country's regulatory authority. In Indonesia, the role is carried out by the Indonesia Food and Drug Administration (BPOM). This study proposes analyzing the manifestation of the principles of the New Public Service in issuing EUA for the COVID-19 vaccine. This research uses qualitative methods through secondary data analysis on written sources of information such as websites, reports, social media, books, and journals. Based on the analysis, in issuing the EUA COVID-19 vaccine, BPOM has performed the principles of the New Public Service. BPOM, with all stakeholders, insisted on their values (quality, safety, and efficacy) to facilitate the EUA process due to the urgency of the emergency. With this effort, the public can afford vaccines that safe and meet the efficacy and quality standard within the expected time.Keywords : COVID-19, Emergency Use Authorization, Indonesia FDA, New Public Service